encourag growth recon area long-term om guidanc
set stage improv ep growth pt
maintain buy rate rais pt
follow result report exceed
estim revenu report xfx beat
btig/consensu estim adj ep exceed
estim call result propel improv result
domest knee xfx overal america aid rosa sale
account half knee growth strength across asia pacif continu
out-performance dental spine cmf laggard xfx
xfx expect continu invest growth particularli within
 target consist msd growth guidanc establish essenti
in-lin street estim call xfx revenu growth rang
ep rang respect
midpoint focu center restructur initi
roll drive omx time cadenc like non-linear firm goal
om establish given combin improv top-lin
perform long-term om goal believ investor gain increas
confid zbh abil drive long-term ep growth think zbh multipl
may move higher result near-term see easier comp buoy
new product introduct help support top-lin momentum
restructur unlock leverag management unveil multi-year restructur plan
drive oper leverag cash flow gener program
invest target annual cost
save drive om level management emphas
timelin margin expans linear unlik see
signific expans path toward oper leverag clearli
laid give greater option accret cash deploy
increas management note opportun given
wonder bandwidth take
midst larg restructur
rosa drive growth management call slightli half knee growth
 driven rosa impli revenu gener rosa
knee system system placement earli util also strong
procedur perform date view drive
market share gain given commerci strategi rosa initi custom site
exist user growth continu system
come comp support addit indic
knee hip management note partial knee hip could revis
knee long-term expect detail aao march
north warsaw facil progress follow anoth inspect fda
agenc came back addit request facil improv cost
respond request earmark factor
guidanc feel neg surpris front increasingli unlik
valuat rate buy pt base mo ep
estim risk discuss
idc btig estim compani document
million except per share amount
made signific improv turnaround busi risk tabl believ
major manufactur cultur challeng exist prior diminsh expect improv
growth profil move progress higher result wamgr see
upsid expect base market interest rosa new product launch top-lin
improv subsequ expect adj ebitda margin improv modestli result better
launch rosa spine
anticip impact sale forc special
on-going roll-out persona revis
potenti realiz initi sg improv
base case scenario fall middl guidanc
estim revenu rise report basi xfx compar
guidanc call xfx growth forecast ep
middl guid rang
upsid estim could come faster expect adopt npi
reinvigor sale forc stronger product addit upsid could
seen greater rosa placement rapid adopt new
indic upsid could seen rapid realiz
oper leverag restructur initi
downsid like come wors expect uptak npi
worsen moral competit loss sale forc worsen margin
push competit account downsid could seen
disappoint rosa launch delay npi longer expect
costli restructur plan
zimmer biomet diversifi
medic technolog compani
design manufactur broad
rang orthopaed reconstruct
product zimmer hold
found justin
zimmer took current
form zimmer acquir
biomet inc april today
zimmer biomet oper global
countri
employe across world
zimmer biomet report result overal revenu came y/i y/i xfx beat btig
consensu expect y/i y/i respect segment report
revenu y/i knee y/i hip y/i y/i
dental y/i spine cmf y/i compar btig/consensu estim
y/i y/i y/i constant currenc revenu growth
btig expect
gross margin adjust compar btig estim sg percentag revenu came
versu btig estim call revenu in-lin btig estim told
adjust ep quarter btig consensu estim
made follow chang model
within zbh revenu mix made modest tweak forward estim slightli increas expect
knee america slightli better expect major minor chang come area
dental believ improv driven new product invest sale drive growth
actualsbtig estimate variancetot net bpssg spend bpsr spend bpsadj ebit bpsadj ebitda bpstax bpssourc btig research estim compani filingsvari
 tweak gm result extra bill day lower gm slightli off-set
come headwind capit inventori cost outsid factor tweak
oper expens slightli overal number unchang
zimmer biomet rate buy pt base month ep estim larg cap med-tech
peer current trade ntm ep trade ntm ep believ multipl appropri
given histor valuat spread rel ihi typic trade ihi impli risk
rate pt includ loss market share competitor inabl remov risk relat manufactur
slower rosa commerci anticip lack consist execut goal lack margin expans
due increas invest
btig research estim compani filingsnewold chang
incom etot y/i sale special oper incom incom tax expens net share net incom share gross net net oper tax expens btig research estim compani report
revenu y/i btig research estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
